Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Panelists discuss the expanding treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer, highlighting the benefits and limitations of FDA-approved therapies like ...

In the following interview, co-author and panel member Benjamin M. Brucker, MD, provides a detailed walkthrough of these guidelines and discusses their practical implications for clinicians.He ...

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Diane K. Newman, DNP, a nationally recognized expert in pelvic health, to explore the often-overlooked yet vitally ...

In the phase 2 COMRADE trial (NCT03317392), reduced-dose olaparib (Lynparza) combined with radium-223 (Ra-223, Xofigo) significantly improved radiographic progression-free survival (rPFS) over Ra-223 ...

Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access ...

Treatment with BCG plus mitomycin demonstrated comparable efficacy and safety to BCG alone while leading to fewer treatment discontinuations and fewer BCG doses in patients with non–muscle invasive ...

Panelists discuss how PET imaging for kidney cancer includes prostate-specific membrane antigen, which is sometimes expressed in renal cell carcinoma, though its utility remains unclear, whereas ...

The combination of zanzalintinib and nivolumab (Opdivo) showed promising efficacy and manageable safety in previously untreated stage 4 renal cell carcinoma (RCC), with a 63% response rate and ...

Discrepancies between the 2 training pathways extend beyond residency, with differences in both practice patterns and physician demographics. Research across various specialties and with diverse ...

On April 26, 2025, Urology Times® hosted a Clinical Forum program during the American Urological Association 2025 Annual Meeting in Las Vegas, Nevada.During the event, experts in bladder cancer care ...

Five-year data from the phase 3 ARCHES trial (NCT02677896) showed that enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) continued to provide a substantial and durable benefit in overall ...